Glenmede Trust’s Alaunos Therapeutics TCRT Stock Holding History

Glenmede Trust’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-133	Closed	-$2.64K	–	1342
2023 Q3	$2.64K	Hold	133	–	–	﹤0.01%	1249
2023 Q2	$12.6K	Hold	133	–	–	﹤0.01%	1247
2023 Q1	$12.6K	Hold	133	–	–	﹤0.01%	1253
2022 Q4	$13K	Hold	133	–	–	﹤0.01%	1248
2022 Q3	$34K	Hold	133	–	–	﹤0.01%	1198
2022 Q2	$24K	Sell	133 -4	-3%	-$382	﹤0.01%	1228
2022 Q1	$13K	Hold	137	–	–	﹤0.01%	1286
2021 Q4	$22K	Hold	137	–	–	﹤0.01%	1275
2021 Q3	$37K	Buy	137 +4	+3%	+$1.22K	﹤0.01%	1222
2021 Q2	$52K	Buy	+133	New	+$62.1K	﹤0.01%	1204
2020 Q3	–	Sell	-6	Closed	-$2K	–	2583
2020 Q2	$2K	Buy	+6	New	+$2.67K	﹤0.01%	2271
2014 Q3	–	Sell	-4	Closed	-$2K	–	2511
2014 Q2	$2K	Hold	4	–	–	﹤0.01%	2250
2014 Q1	$2K	Hold	4	–	–	﹤0.01%	2252
2013 Q4	$2K	Buy	+4	New	+$2.38K	﹤0.01%	2216

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCA

Magnolia Capital Advisors Jackson, Mississippi $509M AUM 18.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Glenmede Trust's TCRT Position: Q4 2023 in Review

Glenmede Trust sold out of Alaunos Therapeutics (TCRT) in Q4 2023, closing a stake of 133 shares — an estimated $2.64K sold.

Glenmede Trust first reported a position in TCRT in Q4 2013 and held it in 14 quarters. The position peaked at $52K in Q2 2021. 82 funds tracked by Wall St. Rank hold TCRT as of Q4 2023.

Glenmede Trust reported no remaining Alaunos Therapeutics position as of Q4 2023 after selling out during the quarter.
Glenmede Trust sold 133 Alaunos Therapeutics shares in Q4 2023, an estimated $2.64K.
Glenmede Trust first reported a position in Alaunos Therapeutics in Q4 2013 and held it in 14 quarters.
Glenmede Trust's Alaunos Therapeutics position peaked at $52K in Q2 2021.
82 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2023.

Based on Glenmede Trust's 13F filing for Q4 2023, filed 13 Feb 2024.